Lifeward Posts $5.5M Adjusted Loss as Q3 Revenue Hits $5.4M
LFWD sits 38% above its 52-week low of $4.14.
Summary
Lifeward reported a Q3 adjusted net loss of $5.5 million and a GAAP net loss of $5.052 million on revenue of $5.428 million, which fell 12% as ReWalk sales declined. Gross margin came in at 27.4% while operating expenses ran $7.457 million, so the cost base still outruns gross profit by a wide margin. Basic EPS was -$1.32 and adjusted EPS -$1.44. The loss is smaller than the $11.5 million net loss reported in Q2, but the company reaffirmed a going concern warning in August, saying cash is insufficient for the next 12 months. That warning plus the October shareholder vote removing the Nasdaq Exchange Cap — which unlocks conversion of the Notes and warrants — makes dilution the central issue for the equity. The interim CEO transition (Mark Grant out, Josh Hexter in) and the CFO churn (Rami Aviram withdrew, Ronen Tsimerman now starts November 1) add execution risk on top of the cash burn.
At the time of this announcement, LFWD was trading at $5.72 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $16.2M. The 52-week trading range was $4.14 to $9.61. This news item was assessed with negative market sentiment and an importance score of 7 out of 10. Source: Reuters.